For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Helicobacter pylori (H. pylori) is a Gram-negative, microaerobic human pathogen and H. pylori infection is strongly related with many gastroduodenal diseases including chronic active gastritis, peptic ulcer diseases, atrophic gastritis, mucosa associated lymphoid tissue (MALT) lymphoma and noncardia gastric cancer. H. pylori infection affects more than half of the adult population worldwide, but the prevalence of H pylori infection varies widely by geographic area, age, race, and socioeconomic status. Usually, the prevalence of H. pylori increases with age in most countries, however a decline in prevalence of H. pylori infection has been observed in recent decades in time trend analysis of several large populations. More than 80% of peptic ulcer diseases are caused by H. pylori infection and the estimated lifetime risk for peptic ulcer disease in H. pylori-infected patients is approximately 15%. Gastric cancer is the third leading cause of cancer-related death worldwide and H. pylori infection is responsible for 74.7% of all noncardia gastric cancer cases. Gastric cancer and peptic ulcer together cause more than a million deaths per year in the world and H. pylori infection always is an important health issue. Various diagnostic methods are developed to detect H. pylori infection and diagnostic tests with both high sensitivity and specificity, exceeding 90%, are necessary for accurate diagnosis of H. pylori infection in clinical practice. Although many diagnostic tests are available now, each method has its own advantages, disadvantages, and limitations. The choice of one method or another could be depended on availability and accessibility of diagnostic tests, level of laboratories, clinical conditions of patients, and likelihood ratio of positive and negative tests on different clinical circumstances. Diagnostic tests are usually divided into invasive (endoscopic-based) and noninvasive methods. Invasive diagnostic tests include endoscopic image, histology, rapid urease test, culture, and molecular methods. Non-invasive diagnostic tests included Non-invasive Techniques, stool antigen test, serological, and molecular examinations.
Scope of the Report:
One of the key drivers witnessed in the market is the growing cost-effectiveness of diagnosis and personalized antibiotic therapy. H. pylori bacteria causes ulcer. H. pylori infection requires antibiotic therapy that includes 10-14 days treatment regimen. This treatment regimen comprises of one or two antibiotics such as amoxicillin, tetracycline, metronidazole, or clarithromycin in combination with ranitidine bismuth citrate, bismuth subsalicylate, and a proton pump inhibitor (PPI). Ulcer-related symptoms such as abdominal pain and nausea and inflammation of gastric mucosa can be cured using PPIs or H2 blockers in combination with antibiotics. The cost-effectiveness of antibiotics and the lesser duration of treatment boosts the adoption of antibiotic regimen by healthcare professionals. This in turn, will drive the demand for pre- and post-monitoring tests.
In terms of geography, the Europe accounted for the majority market shares during 2017 and this mainly accounted to the growing prevalence of peptic ulcer disease and gastritis. The increasing patient pool looking for the early detection of symptoms and treatment is boosting the demand for helicobacter pylori diagnostics in the region. Owing to the continuous efforts of vendors to develop a vaccination for H. pylori infection and the introduction of improved diagnostic techniques, the market will continue to witness considerable growth in this region during the next four years as well.
The helicobacter pylori diagnostics market is characterized by the presence of major vendors and is highly competitive. These vendors compete against each other based on factors including pricing, product differentiation, and advancements in technology. Vendors are highly focusing on expanding their product portfolio and increasing investments in acquiring other players, which will help them increase their revenue shares. Additionally, they are also focusing on the development of vaccines and enhancing their presence in the regional and untapped markets.
Hospitals and clinics reduce the overall disease burden and promote health by offering immunoassays and molecular diagnostic techniques. These techniques enable the early diagnosis of infectious and lethal diseases. The patient pool suffering from infectious diseases such as bacterial diseases (enteric bacteria), cancer, and other life-threatening diseases highly rely on hospitals since they have tie-ups with research and developmental centers and research institutes.
The global Helicobacter Pylori Diagnostics market is valued at 480 million USD in 2018 and is expected to reach 740 million USD by the end of 2024, growing at a CAGR of 7.6% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Helicobacter Pylori Diagnostics.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Helicobacter Pylori Diagnostics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Helicobacter Pylori Diagnostics market by product type and applications/end industries.
Market Segment by Companies, this report covers
- Sekisui Diagnostics
- F. Hoffmann-La Roche
- Medline Industries
- Meridian Bioscience
- Bio-Rad Laboratories
- Thermo Fisher Scientific
- Alpha Laboratories
- EKF Diagnostics
- Quidel
- Halyard Health, Inc
- Cardinal Health
- Beckman Coulter Inc
- Agilent Technologies
- Coris BioConcept
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Invasive Techniques
- Non-invasive Techniques
Market Segment by Applications, can be divided into
- Hospitals and Clinics
- Diagnostic Laboratories